Cipla Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.12 lakh crore. The company reports ROE of 8.3%, a net profit margin of 10.4%. Revenue grew -1.1% year-over-year. Promoter holding stands at 31.1%, with FII participation at 45%.
Buying pressure is building (RSI/MACD momentum confirmed). A trend-following indicator is on the bullish side (SuperTrend signal: buy). Each rally is higher than the last, and each dip is shallower (higher highs and higher lows — healthy uptrend structure). Price has pulled back to a natural support zone — a typical re-entry point in an uptrend (Fibonacci 23.6% retracement at ₹1,391). Above-average delivery percentage suggests real buying, not just speculation (delivery 62%). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak). Price is coiled right at its breakout level — the trigger point is imminent (within 0.5% of the key resistance).
Cipla Limited scores 69/100 (Positive Research Signal). The strongest signals are Momentum (13/100) and Trend (12/100). The weakest dimension is Institutional Activity (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.
| Stock | Score | Signal |
|---|---|---|
|
SUNPHARMA
Sun Pharmaceutical Industries Limited
|
84 | High Conviction |
|
AUROPHARMA
Aurobindo Pharma Limited
|
75 | High Conviction |
|
APOLLOHOSP
Apollo Hospitals Enterprise Limited
|
73 | High Conviction |
|
DIVISLAB
Divi's Laboratories Limited
|
72 | High Conviction |
|
GLENMARK
Glenmark Pharmaceuticals Limited
|
60 | Positive Setup |